Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 years

International Journal of Gynecological Cancer

Volumn 20, Issue 5, 2010, Pages 757-765

  Gordon, Louisa G ^a,b   Scuffham, Paul A ^b   Beesley, Vanessa L ^a   Green, Adèle C ^a,b   DeFazio, Anna ^c   Wyld, David K ^d   Clavarino, Alexandra M ^e   Webb, Penelope M ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cost analysis; Ovarian cancer; Quality adjusted life years; Treatment adverse effects

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESPIRATORY DISTRESS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; WOUND INFECTION;

ANTINEOPLASTIC AGENTS; AUSTRALIA; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77956824855     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181dbd13f     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71Y96.
2. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195Y208.
3. NHMRC National Health and Medical Research Council. Clinical Practice Guidelines for the Management of Women With Epithelial Ovarian Cancer. Canberra, Australia: Commonwealth Government; 2004.
4. Doyle C, Crump M, Pintilie M, et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001;19:1266Y1274.
5. Harrison JD, Solomon MJ, Young JM, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg. 2008;143:389Y394.
6. Rocconi RP, Case AS, Straughn JM Jr, et al. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Cancer. 2006;107:536Y543.
7. Dimoska A, Girgis A, Hansen V, et al. Perceived difficulties in consulting with patients and families: A survey of Australian cancer specialists. Med J Aust. 2008;189: 6112Y6615.
8. Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: How, why, and what does it mean? CA Cancer J Clin. 2008;58:231Y244.
9. Case AS, Rocconi RP, Partridge EE, et al. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer. Gynecol Oncol. 2007;105:223Y227.
10. Stewart DJ, Dahrouge S, Coyle D, et al. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol. 1999;17:344Y351.
11. Merritt MA, Green AC, Nagle CM, et al. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer. 2008;122:170Y176.
12. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534Y1535.
13. Johnatty SE, Beesley J, Paul J, et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 2008;14:5594Y5601.
14. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523Y1532.
15. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005.
16. Wan GJ, Counte MA, Cella DF. The influence of personal expectations on cancer patients' reports of health-related quality of life. Psychooncology. 1997;6:1Y11.
17. Weycker D, Malin J, Edelsberg J, et al. Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008; 19:454Y460.
18. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975Y2005. Bethesda, MD: National Cancer Institute; 2008.
19. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol. 1996;49:95Y103.
20. Khan ZM, Rascati KL, Koeller JM. Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer. Pharmacoeconomics. 1999;16:43Y57.